Egypt Sends Plasma to Be Manufactured Into Biopharmaseuticals in Spain
The plasma by-products will help treat rare and chronic diseases such as primary immunodeficiency and cardiopulmonary diseases.
Pharmaceutical company Grifols Egypt has shipped its first installment of plasma to its Spanish counterpart to be manufactured and returned to Egypt as biopharmaceuticals.
The plasma by-products will help treat rare and chronic diseases such as primary immunodeficiency, cardiopulmonary diseases and burn injuries.
This shipment is the first of many under an agreement between Grifols Spain and the Egyptian government, which was signed in November 2020.
Over 20 plasma donation centers are currently being established across the country, in addition to a plasma testing and storage facility in the New Administrative Capital in accordance with the international medical standards.